Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies

scientific article published on 12 January 2016

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.7326/M15-1536
P932PMC publication ID5079106
P698PubMed publication ID26756606

P50authorOğuzhan AlagözQ56654355
Ronald E GangnonQ56810665
Mehmet Ali ErgunQ57334076
Donald H BerryQ73566215
Clyde B SchechterQ87050955
Diana MigliorettiQ88168881
Amy Trentham-DietzQ88960210
Sylvia PlevritisQ89453368
Eveline A M HeijnsdijkQ89500454
Jeanne S MandelblattQ90278289
Eric J FeuerQ90907333
Brian L SpragueQ91924355
Karla KerlikowskeQ92299671
Nicolien T van RavesteynQ98198718
Anna N. A. TostesonQ110143968
Aimee M NearQ114374862
Natasha K StoutQ114563134
Gary ChisholmQ114563136
Jeroen J van den BroekQ114563144
Kathleen A. CroninQ125588542
P2093author name stringHui Huang
Harry J de Koning
Xuelin Huang
Sandra J Lee
Yaojen Chang
Amanda Hoeffken
Diego Munoz
Martin Krapcho
P2860cites workScreening for breast cancer with mammographyQ24202273
Genome-wide association studies identify four ER negative-specific breast cancer risk lociQ24622610
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysisQ24628928
Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methodsQ26824867
The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort modelQ27347267
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statementQ28265041
Cancer screening in elderly patients: a framework for individualized decision makingQ33949364
Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studiesQ33957073
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefitsQ34159375
Prevalence of mammographically dense breasts in the United StatesQ34354391
Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategiesQ34386037
Quantifying the benefits and harms of screening mammographyQ34395037
Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trialQ34403715
Abolishing mammography screening programs? A view from the Swiss Medical Board.Q34415457
Effect of screening and adjuvant therapy on mortality from breast cancerQ34463105
A stochastic model for predicting the mortality of breast cancerQ34573070
Long-term effects of mammography screening: updated overview of the Swedish randomised trialsQ34579899
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortalityQ34736052
Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and MedicineQ34753553
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harmsQ35013356
A reality check for overdiagnosis estimates associated with breast cancer screeningQ35102556
External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and olderQ35171219
Public Opinions about Overdiagnosis: A National Community SurveyQ35629000
Identifying women with dense breasts at high risk for interval cancer: a cohort studyQ35646902
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsQ35740423
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density MeasuresQ35752042
Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortalityQ36438347
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of riskQ36460671
Prediction of breast cancer risk based on profiling with common genetic variantsQ36583004
Performance benchmarks for screening mammographyQ36600843
A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trendsQ36619879
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?Q36659650
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosisQ36770273
Genetic susceptibility to triple-negative breast cancerQ36846498
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapyQ36976948
Benign breast disease, mammographic breast density, and the risk of breast cancerQ37021220
Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort studyQ37054183
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screeningQ37070417
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectivenessQ37139381
Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrolleesQ37169846
Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMIQ37231420
Obesity, mammography use and accuracy, and advanced breast cancer riskQ37324240
Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer.Q37548461
Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patientsQ37601809
Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screeningQ37977324
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studiesQ38042894
European breast cancer service screening outcomes: a first balance sheet of the benefits and harmsQ38225849
Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic reviewQ38296894
Breast-specific gamma imaging: correlations with mammographic and clinicopathologic characteristics of breast cancerQ38437176
A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.Q38465812
Diagnostic performance of digital versus film mammography for breast-cancer screeningQ39730356
Digital breast tomosynthesis and the challenges of implementing an emerging breast cancer screening technology into clinical practiceQ40154748
Breast cancer screening using tomosynthesis in combination with digital mammographyQ40209954
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.Q40261524
Breast-cancer screening--viewpoint of the IARC Working GroupQ41697220
Effect of age, breast density, and family history on the sensitivity of first screening mammographyQ45149178
The value of modern mammography screening in the control of breast cancer: understanding the underpinnings of the current debates.Q50111734
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.Q50192553
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.Q51914599
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.Q51931359
Retrospective cost-effectiveness analysis of screening mammography.Q53241570
Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.Q53474457
Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts.Q53635144
Mammographic Density and the Risk and Detection of Breast CancerQ59545042
Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast CancerQ61881608
The impact of a breast cancer screening programme on quality-adjusted life-yearsQ68009566
The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-upQ74174362
Changing patterns in breast cancer incidence trendsQ79220373
The Wisconsin Breast Cancer Epidemiology Simulation ModelQ79220380
Prospective breast cancer risk prediction model for women undergoing screening mammographyQ80216670
The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapyQ86069475
The harms and benefits of modern screening mammographyQ88098170
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectcollaborationQ1145523
breast cancer screeningQ17011492
P304page(s)215-225
P577publication date2016-01-12
P1433published inAnnals of Internal MedicineQ564416
P1476titleCollaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies
P478volume164

Reverse relations

cites work (P2860)
Q38669521A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality.
Q92199197A systematic review and quality assessment of individualised breast cancer risk prediction models
Q60175951Breast Cancer Incidence by Stage Before and After Change in Screening Guidelines
Q30238753Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
Q64461485Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling
Q92528444Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification
Q47304201Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
Q51738443Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.
Q51738440Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.
Q46212925Comparison of recommendations for screening mammography using CISNET models
Q64461488Contribution of Breast Cancer to Overall Mortality for US Women
Q47198620Cost Effectiveness of Gene Expression Profile Testing in Community Practice.
Q88960776Cost-Effectiveness of Breast Cancer Screening in Turkey, a Developing Country: Results from Bahçeşehir Mammography Screening Project
Q47218784Distinguishing between CISNET model results versus CISNET models
Q47336549Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study
Q52350449Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
Q91895021Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool
Q48104203Estimating the frequency of indolent breast cancer in screening trials
Q33859917Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force
Q49571883Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women.
Q64109359Factors associated with false-positive mammography at first screen in an Asian population
Q33763563Imaging Surveillance After Primary Breast Cancer Treatment
Q88098279Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models
Q64935691Is risk-stratified breast cancer screening economically efficient in Germany?
Q56334456Linkage of the ACR National Mammography Database to the Network of State Cancer Registries: Proof of Concept Evaluation by the ACR National Mammography Database Committee
Q88098258Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches
Q48369270Opportunity cost of annual screening mammography.
Q89622252Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy
Q37720423Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?
Q91894841PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity
Q37567500Persuasive Interventions for Controversial Cancer Screening Recommendations: Testing a Novel Approach to Help Patients Make Evidence-Based Decisions.
Q49920221Physicians discuss ramifications of studies pointing to breast cancer overdiagnosis: New research under way attempts to better define who should be screened and treated.
Q30251601Population-based screening for cancer: hope and hype.
Q44876590Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes.
Q36908218Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms
Q42370817Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms--Reply
Q48348309Reply to Distinguishing between CISNET model results versus CISNET models.
Q46841562Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors
Q39347821Risk-based Breast Cancer Screening: Implications of Breast Density
Q90590047Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age
Q49589211Short- and Long-Term (10-year) Results of an Organized, Population-Based Breast Cancer Screening Program: Comparative, Observational Study from Hungary.
Q52648599Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.
Q88541401Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer
Q52648603Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.
Q37444608Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes
Q47130981The Complexity of Achieving the Promise of Precision Breast Cancer Screening.
Q52648600The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update.
Q60175954Trends in breast cancer mortality by stage at diagnosis among young women in the United States
Q90585615Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance
Q51365548Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.
Q50281308Validating a breast cancer score in Spanish women. The MCC-Spain study.
Q55315231Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals.

Search more.